source
- Novartis MS drug remibrutinib cuts relapse rates by about a third in Phase 3 trialsData presented at an MS conference in Toronto showed that Novartis' experimental therapy, remibrutinib, reduced the annualized relapse rate in relapsing‑remitting multiple sclerosis by roughly 35%…
- US proposes new biotech investment limits on China, but licensing deals remain allowedThe U.S. Treasury announced a proposal to curb outbound investments in Chinese biotechnology, citing national‑security concerns. The plan would limit U.S. persons from funding certain bio‑derived c…